Ambs S, Merriam W G, Bennett W P, Felley-Bosco E, Ogunfusika M O, Oser S M, Klein S, Shields P G, Billiar T R, Harris C C
Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA.
Cancer Res. 1998 Jan 15;58(2):334-41.
An increased expression of nitric oxide synthase (NOS) has been observed in human colon carcinoma cell lines as well as in human gynecological, breast, and central nervous system tumors. This observation suggests a pathobiological role of tumor-associated NO production. Hence, we investigated NOS expression in human colon cancer in respect to tumor staging, NOS-expressing cell type(s), nitrotyrosine formation, inflammation, and vascular endothelial growth factor expression. Ca2+-dependent NOS activity was found in normal colon and in tumors but was significantly decreased in adenomas (P < 0.001) and carcinomas (Dukes' stages A-D: P < 0.002). Ca2+-independent NOS activity, indicating inducible NOS (NOS2), is markedly expressed in approximately 60% of human colon adenomas (P < 0.001 versus normal tissues) and in 20-25% of colon carcinomas (P < 0.01 versus normal tissues). Only low levels were found in the surrounding normal tissue. NOS2 activity decreased with increasing tumor stage (Dukes' A-D) and was lowest in colon metastases to liver and lung. NOS2 was detected in tissue mononuclear cells (TMCs), endothelium, and tumor epithelium. There was a statistically significant correlation between NOS2 enzymatic activity and the level of NOS2 protein detected by immunohistochemistry (P < 0.01). Western blot analysis of tumor extracts with Ca2+-independent NOS activity showed up to three distinct NOS2 protein bands at Mr 125,000-Mr 138,000. The same protein bands were heavily tyrosine-phosphorylated in some tumor tissues. TMCs, but not the tumor epithelium, were immunopositive using a polyclonal anti-nitrotyrosine antibody. However, only a subset of the NOS2-expressing TMCs stained positively for 3-nitrotyrosine, which is a marker for peroxynitrite formation. Furthermore, vascular endothelial growth factor expression was detected in adenomas expressing NOS2. These data are consistent with the hypothesis that excessive NO production by NOS2 may contribute to the pathogenesis of colon cancer progression at the transition of colon adenoma to carcinoma in situ.
在人结肠癌细胞系以及人妇科、乳腺和中枢神经系统肿瘤中,已观察到一氧化氮合酶(NOS)表达增加。这一观察结果提示肿瘤相关的NO产生具有病理生物学作用。因此,我们从肿瘤分期、表达NOS的细胞类型、硝基酪氨酸形成、炎症以及血管内皮生长因子表达等方面研究了人结肠癌中的NOS表达。在正常结肠和肿瘤中发现了Ca2+依赖性NOS活性,但在腺瘤(P < 0.001)和癌(杜克分期A - D:P < 0.002)中显著降低。Ca2+非依赖性NOS活性表明诱导型NOS(NOS2),在约60%的人结肠腺瘤中显著表达(与正常组织相比,P < 0.001),在20 - 25%的结肠癌中表达(与正常组织相比,P < 0.01)。在周围正常组织中仅发现低水平表达。NOS2活性随肿瘤分期增加(杜克分期A - D)而降低,在肝和肺的结肠转移瘤中最低。在组织单核细胞(TMC)、内皮细胞和肿瘤上皮细胞中检测到NOS2。NOS2酶活性与免疫组化检测到的NOS2蛋白水平之间存在统计学显著相关性(P < 0.01)。对具有Ca2+非依赖性NOS活性的肿瘤提取物进行蛋白质印迹分析,在Mr 125,000 - Mr 138,000处显示出多达三条不同的NOS2蛋白条带。在一些肿瘤组织中,相同的蛋白条带高度酪氨酸磷酸化。使用多克隆抗硝基酪氨酸抗体,TMC呈免疫阳性,但肿瘤上皮细胞不呈免疫阳性。然而,仅一部分表达NOS2的TMC对3 - 硝基酪氨酸染色呈阳性,3 - 硝基酪氨酸是过氧亚硝酸盐形成的标志物。此外,在表达NOS2的腺瘤中检测到血管内皮生长因子表达。这些数据与以下假设一致,即NOS2产生的过量NO可能在结肠腺瘤向原位癌转变过程中促进结肠癌进展的发病机制。